21 May 2009
New tools for defining immune stability in long-term recipients of kidney allograft
J SoulillouAnn Transplant 2009; 14(1): 12-12 :: ID: 880239
Abstract
The study of biological correlates associated with state of operational acceptance of mismatched kidney grafts years after of total interruption of immunosuppressive drugs on one side, and the growing information concerning biomarkers associated with chronic rejection may contribute to a better understanding of the status of "stable patients" years following transplantation. This understanding is crucial for guiding eventual minimalisation on weaning of immunosuppressive drugs. Recently, our laboratory has described several biological correlates with immunosuppressive drug free operational acceptance of kidney graft, including phenotypes and transcriptional alterations. Similarly, we have described a series of blood biomarkers increased (TLR4, Trib1, PSMB10) or decreased (granzyme B) in the blood of patients with chronic active rejection associated with DSA. Using these acceptance or rejection biomarkers, we screened a cohort of 164 patients presenting a highly stable clinical status at more than five years after transplantation. We show that these patients do not express the rejection associated set of biomarkers. However, according to the stringency of the analysis, few patients, of these patients under dual therapy, exhibit the operational acceptance signature (<5%). Longer follow up of these stable patients also show that a minority of them (~10%) have degraded their function with time. Grafts biopsies of these patients did not evidence chronic rejection symptom, excepted in one case but show aspecific lesions (toxicity, relapse or LAN). Despite this late degradation was not related to chronic rejection, DNAchips performed on these patients at the time of their highly stable status discriminated this outcome suggesting that an "aspecific" infl ammation status can be monitored. Collectively we hope that these data will set more scientific bases for protocols aimed at weaning CNI or other immunosuppressive drugs.
Keywords: immunosuppressive drugs, biomarkers, Transplantation
Most Viewed Current Articles
26 Jan 2022 : Review article
Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive ModelsDOI :10.12659/AOT.934924
Ann Transplant 2022; 27:e934924
24 Aug 2021 : Review article
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original article
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860